R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 49.6 CNY -4.39% Market Closed
Market Cap: 4.8B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Deferred Income Tax

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Deferred Income Tax Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Deferred Income Tax CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Deferred Income Tax
ÂĄ1.8m
CAGR 3-Years
209%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Deferred Income Tax
ÂĄ596.9m
CAGR 3-Years
27%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Deferred Income Tax
ÂĄ241.5m
CAGR 3-Years
28%
CAGR 5-Years
46%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Deferred Income Tax
ÂĄ107.1m
CAGR 3-Years
-18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Deferred Income Tax
ÂĄ208.7m
CAGR 3-Years
14%
CAGR 5-Years
84%
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
59.36 CNY
Undervaluation 16%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Deferred Income Tax?
Deferred Income Tax
1.8m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Deferred Income Tax amounts to 1.8m CNY.

What is R&G PharmaStudies Co Ltd's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 3Y
209%

Over the last year, the Deferred Income Tax growth was -27%. The average annual Deferred Income Tax growth rates for R&G PharmaStudies Co Ltd have been 209% over the past three years .

Back to Top